MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin.
about
Treatment for mitochondrial disordersTreatment for mitochondrial disordersA microdeletion in cytochrome c oxidase (COX) subunit III associated with COX deficiency and recurrent myoglobinuriaMitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current conceptsMuscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disordersRoles for imaging in understanding the pathophysiology, clinical evaluation, and management of patients with mitochondrial disease.Applications of magnetic resonance spectroscopy to diagnosis and monitoring of mitochondrial disease.Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy.Alternative headache treatments: nutraceuticals, behavioral and physical treatments.MELAS syndromeTargeting cellular energy production in neurological disorders.CoEnzyme Q10 and riboflavin: the mitochondrial connection.Epidemiology and treatment of mitochondrial disorders.Migraine: preventive treatment.Riboflavin prophylaxis in pediatric and adolescent migraineConvergent mechanisms in etiologically-diverse dystoniasThe mitochondrial myopathy encephalopathy, lactic acidosis with stroke-like episodes (MELAS) syndrome: a review of treatment options.Diagnosis and treatment of mitochondrial myopathiesDiagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.In vivo mitochondrial function in HIV-infected persons treated with contemporary anti-retroviral therapy: a magnetic resonance spectroscopy study.Neuroprotective effects of free radical scavengers and energy repletion in animal models of neurodegenerative disease.The treatment of congenital lactic acidoses.Impairment of central and peripheral myelin in mitochondrial diseases.Application of NMR spectroscopy to monitoring MELAS treatment: a case report.A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial.Prophylactic Therapy for Migraine.Monitoring clinical progression with mitochondrial disease biomarkers.Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.Riboflavin in cyclic vomiting syndrome: efficacy in three children.Advances in the Treatment of MELAS Syndrome: Could Cognitive Rehabilitation Have a Role?High-dose riboflavin as a prophylactic treatment of migraine: results of an open pilot study.The Main Molecular Mechanisms Underlying Methamphetamine- Induced Neurotoxicity and Implications for Pharmacological Treatment.Riboflavin-responsive oxidative phosphorylation complex I deficiency caused by defective ACAD9: new function for an old gene
P2860
Q24200432-650873EF-69F4-4330-9CA7-1C0F8724DBAAQ24244543-73F1F99B-E473-4C7F-919B-12E2A3CFF8ABQ28115983-89998ABA-7EC0-473F-9396-F158DE23C188Q28251780-10AAF5DD-DB12-4796-A441-366465A0086FQ28820743-642EDD9F-610B-4783-948F-F41C3A882C70Q30882578-DF3408B5-DFA0-4D25-BBD3-2373C85934D2Q32101242-B8066C02-5324-4A67-A39E-60E18EF463ABQ33527398-DAE92852-9501-4B99-B9A3-A60C09417A03Q34010163-1A63CFCE-D7B6-4505-B856-847CB8421E69Q34166923-47891BD7-F539-4811-9CC8-8AB1A85E7DBDQ34182102-275B9709-C679-4CE6-AC69-783900F4A2BBQ34266266-3A8DA232-1CFE-4CC7-812C-D935B84CF396Q34303464-35FC396B-1D67-4F4A-AEB3-1AA51B9A2833Q34386766-911C6CE9-C292-4863-9AC6-56684C7EA352Q34852689-99EF6B22-7FA1-44F7-B1CA-978399D4D1EBQ36260702-65F9E8D7-B00E-4162-A871-0B4C678C94F7Q36445234-FC8D5194-7F58-425B-9B47-A7BAAEA4752FQ36492305-CFF61644-AFBC-4230-B5BD-4F37A0A50E0DQ36634939-D090ADA2-4B0D-4425-BB20-6B0F4BC74E8AQ37210464-550CDE8C-C5A1-4BFE-B583-C67C5F7D44AEQ37444962-FEFC1223-8FAC-402A-B0FB-54456F1472E5Q40374461-1D406622-FC85-4D98-8268-F764662C6B32Q41180888-51D220A5-9A3C-4CE3-BCA9-D5D657C30A45Q41378824-27EE026A-8066-45C6-8B77-DBB632E2A2A0Q43947382-5561A81F-5ADC-446B-8DF0-3814592C0BD0Q45077713-4FE61A9E-090D-40CA-9782-F57820CCB765Q47311786-88D96A40-987D-4E91-B19B-803CECDE933DQ47713915-2316FDC4-6621-4B46-AB18-BE94F2D4F813Q47988632-98025408-B074-4FEA-8EF7-9BDD3DE15BBAQ48969987-33B43D94-006D-41C5-8045-C74D37B4F0FDQ53343108-49415349-54EF-42F2-AC82-EAEF5BE976E5Q54023124-9D16F684-5311-4767-BB6E-CC34E89B0C35Q55284097-0BB0AC05-D0D0-43DA-8917-F0E95A2B06B8Q57987777-5B72ED95-665F-4A40-8F9D-4D860AF1B95B
P2860
MELAS syndrome with mitochondrial tRNA(Leu)(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh-hant
name
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@en
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@nl
type
label
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@en
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@nl
prefLabel
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@en
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@nl
P2093
P356
P1433
P1476
MELAS syndrome with mitochondr ...... h nicotinamide and riboflavin.
@en
P2093
Kennaway NG
Maclure KM
Thuillier P
P304
P356
10.1212/WNL.42.11.2147
P407
P577
1992-11-01T00:00:00Z